Pathways were analysed with Ingenuity Pathway Analysis (IPA). Normalization and differential expression was done using DESeq2 R package. RNA was extracted and single-end RNA sequencing was performed using Illumina HiSeq4000. Similarly, inflamed colonic biopsies (15 UC, 9 CD) were collected from 24 patients initiating anti-TNF therapy (Table 1). We obtained inflamed colonic biopsies from 31 patients (20 UC, 11 CD) prior to initiation of vedolizumab.
Due to the increasing availability of therapeutic compounds in inflammatory bowel disease (IBD), predictive biomarkers are urgently awaited in order to help clinicians decide between anti-TNF, vedolizumab or other therapies.Īim We aimed to identify baseline transcriptomic profiles in inflamed colonic biopsies predicting vedolizumab-induced endoscopic remission. Vedolizumab, a monoclonal antibody targeting alpha4beta7 integrin and mainly inhibiting gut lymphocyte trafficking, has been approved for the treatment of both Crohn's disease (CD) and ulcerative colitis (UC).
FERRANTE (3) / Translational Research Center for Gastrointestinal Disorders (TARGID), KULeuven, Leuven, Belgium, Department of Chronic Diseases, metabolism and ageing, Laboratory for Complex Genetics, KU Leuven,, Belgium, Department of Human genetics, Translational Research Center for Gastrointestinal Disorders (TARGID), KULeuven, Leuven, Belgium, Department of Chronic Disease, Metabolism and Ageing, Laboratory of Lipid Metabolism and Cancer, KU Leuven,, Belgium, Department of Oncology